1. Liquidia's stock price surged from $11.76 to $22.74 in Q3 2025, driven by strong market performance; 2. The FDA approved Yutrepia, Liquidia's flagship product, in May 2025, marking a critical milestone; 3. Upcoming corporate updates are expected to influence the stock price, making the next month pivotal for investors.